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Abstract 
Aims: The rates of hypoglycaemia reported in clinical trials are affected by the definitions of 
hypoglycaemia used. This post-hoc analysis took data from two trials comparing the once-daily, fixed 
ratio combination of insulin degludec/liraglutide (IDegLira) with basal insulin regimens, and re-
analysed these data using alternative hypoglycaemia definitions and stratified outcomes by dosing 
time and baseline characteristics. 
Materials and methods: Post hoc analyses of the DUAL I (patients uncontrolled on oral antidiabetic 
drugs) and DUAL V (patients uncontrolled on insulin glargine (IGlar) U100) trials were carried out 
using different definitions of hypoglycaemia and by whether treatments were administered in the 
AM or PM. Rates of hypoglycaemia for the definitions of confirmed and ADA-documented 
symptomatic hypoglycaemia were compared according to age, gender and BMI.  
Results: Although hypoglycaemia rates differed with the alternative hypoglycaemia definitions, rates 
were consistently lower with IDegLira versus IDeg and IGlar U100. Despite HbA1c being lower with 
IDegLira at end of treatment, confirmed and nocturnal-confirmed hypoglycaemia rates were lower 
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for IDegLira versus IDeg and IGlar U100, irrespective of dosing time. The definitions of confirmed and 
ADA documented symptomatic hypoglycaemia did not have a significant effect on the treatment 
difference between IDegLira and IDeg, liraglutide or IGlar U100 when further assessed by baseline 
age, gender and BMI. 
Conclusions: Treatment with IDegLira, versus IDeg and IGlar U100, resulted in lower rates of 
hypoglycaemia regardless of dosing time and definition of hypoglycaemia used. The choice of 
hypoglycaemia definition did not influence the results of analyses when stratified by age, sex and 
BMI. 
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Introduction 
Insulin degludec/liraglutide (IDegLira) is a once-daily combination of insulin degludec (IDeg), a basal 
insulin with a long duration of action,
1
 and the glucagon-like peptide-1 receptor agonist (GLP-1 RA), 
liraglutide. In clinical trials, IDegLira has been associated with lower rates of hypoglycaemia versus 
the basal insulin comparators of IDeg (in the DUAL I clinical trial, NCT01336023
2
) and insulin glargine 
(IGlar) U100 (in the DUAL V clinical trial, NCT01952145
3
), despite achieving significantly better 
glycaemic control.  
The purpose of the current study was to re-analyse, using a series of alternative hypoglycaemia 
definitions, data from two trials, DUAL I and V, in which IDegLira was compared with basal insulin 
therapy. In the DUAL I and DUAL V trials, the original definition of confirmed hypoglycaemia used 
was plasma glucose (PG) <3.1 mmol/L (<56 mg/dL) or patient unable to self-treat, and an episode 
was classified as nocturnal hypoglycaemia if occurring between 00:01 and 05:59 (both inclusive). 
Several other definitions of hypoglycaemia are described in the literature, however, and have been 
used across different diabetes clinical trials,
4
 and the rates of hypoglycaemia reported in a clinical 
trial will inevitably be affected by the definitions used.
5
 Recently the International Hypoglycaemia 
Study Group released a joint ADA/EASD statement stating that a single glucose level should be 
agreed to, which would allow efficacy of intervention comparisons to be made with greater 
statistical power.
6
 It is also possible that any differences in outcomes associated with differing dosing 
times, for example the rate of nocturnal hypoglycaemia, could be masked by the overall 
hypoglycaemia advantages reported for IDegLira in these studies. Therefore, the hypoglycaemia 
results were also analysed by dosing time, and by varying the definition of the nocturnal period to 
better characterise the clinical profile of IDegLira with regard to its relative risks for hypoglycaemia. 
In addition, previous analyses have shown that IDegLira is efficacious regardless of baseline 
characteristics, such as BMI
7 
and HbA1c.
8
 This analysis therefore assessed whether the relative risk of 
hypoglycaemia was influenced by key baseline characteristics, again using the different definitions. 
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Material and Methods  
The DUAL I clinical trial compared the efficacy and safety of IDegLira to its individual components, in 
insulin-naïve patients with type 2 diabetes previously uncontrolled on metformin +/- pioglitazone. 
Patients were randomized 2:1:1 to receive IDegLira (N=834), IDeg (N=414) or liraglutide (N=415) 
over the 26-week main trial period;
2
 1311 patients continued treatment into the 26-week extension 
period (ext); N=665, 333 and 313 for IDegLira, IDeg and liraglutide, respectively.
7
 IDegLira treatment 
was initiated at 10 dose steps daily (10 units of IDeg plus 0.36 mg of liraglutide); similarly, IDeg 
treatment was initiated at 10 units daily. Liraglutide treatment was initiated at a daily dose of 0.6 
mg, increased by 0.6 mg each week until a final dose of 1.8 mg/day was reached. IDegLira and IDeg 
were titrated twice-weekly to a fasting plasma glucose target of 45 mmol/L (7290 mg/dL), with a 
maximum dose of 50 dose steps for IDegLira, but no maximum dose for IDeg.
7
  
In the DUAL V trial, IDegLira was compared with continued up-titration of IGlar U100 in patients with 
type 2 diabetes previously uncontrolled on IGlar U100 (2050 units daily) and metformin.
3
 There 
were 557 patients randomized 1:1 to receive IDegLira or IGlar U100 (N=278 and 279, respectively) 
over a 26-week period. IDegLira was initiated at 16 dose steps (16 units of IDeg plus 0.58 mg of 
liraglutide) administered once-daily at any time of day, although preferably at the same time of day 
throughout the trial. Meanwhile IGlar U100 was continued at pre-trial daily dose and administered 
once-daily according to local prescribing instructions. Similarly to DUAL I, IDegLira and IGlar U100 
were titrated twice-weekly to a fasting plasma glucose target of 45 mmol/L with a maximum dose 
of 50 dose steps for IDegLira, but no maximum dose for IGlar U100.
3
  
Post hoc analyses of the DUAL I/ext and DUAL V trial data were carried out according to different 
definitions of hypoglycaemia (Table 1) and according to whether both treatments were administered 
in the AM (00:0011:59 h) or the PM (12:0023:59 h). In addition, the rates of hypoglycaemia for the 
definitions of confirmed hypoglycaemia and ADA documented symptomatic hypoglycaemia were 
compared with patient data stratified according to the baseline characteristics of age (<65 and д65 
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years), gender and body mass index (BMI) (<25, д25<30, д30<35 and д35 kg/m2). The proportions 
of patients achieving an HbA1c of either less than 7% or less than or equal to 6.5%, the proportions 
achieving these targets with no confirmed hypoglycaemia, and those achieving these targets with no 
confirmed hypoglycaemia and no weight gain, has been described previously for DUAL I
2
 and DUAL 
V;
3
 hypoglycaemia was defined in these reports as the patient unable to self-treat or plasma glucose 
<3.1 mmol/L (<56 mg/dL). The current post-hoc analysis examined the same endpoints using the 
ADA documented symptomatic hypoglycaemia definition (Table 1). Protocols were approved by 
institutional review boards and studies were done in accordance with the Declaration of Helsinki.  
 
Statistical methods 
The number of hypoglycaemic events according to the definition of hypoglycaemia, dosing time and 
baseline characteristics was analysed based on the full analysis set using a negative binomial 
regression model with a log link and the logarithm of the time period in which a hypoglycaemic 
episode is considered treatment emergent as offset. The model includes treatment, country/region 
and relevant stratification factors (in DUAL I/ext only) of previous OAD treatment, baseline HbA1c 
stratum; and substudy participation as fixed effects. Analyses of hypoglycaemia according to 
baseline characteristics further included the baseline group and an interaction term between 
baseline group and treatment as fixed effects in the model. For the proportion of patients achieving 
HbA1c targets, odds ratios were estimated from a logistic regression model with treatment, region, 
and relevant stratification factors as fixed factors and baseline HbA1c and weight, when weight was 
included in the composite, as covariates.  
 
Results 
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Hypoglycaemia rates according to different definitions 
Regardless of the hypoglycaemia definition used, rates of hypoglycaemia were lower in patients 
treated with IDegLira than with IDeg, for both DUAL I and DUAL I ext, or with IGlar U100 in DUAL V, 
but higher than in patients treated with liraglutide, for both DUAL I and DUAL I ext (Table 2). The 
lower hypoglycaemia rates in comparison with basal insulin therapy with IDeg or IGlar U100 were 
achieved despite significantly greater end of trial HbA1c reductions with IDegLira therapy.
2,3,7
  
Hypoglycaemia estimated rate ratios by treatment were statistically significantly lower for patients 
treated with IDegLira compared with IDeg or IGlar U100 for all definitions of overall hypoglycaemia, 
including confirmed symptomatic and ADA-documented symptomatic episodes (DUAL I ext and 
DUAL V shown in Figure 1, DUAL I shown in Supplementary Figure 1). Very few of the total 
hypoglycaemia events were categorized as severe (an episode requiring assistance of another 
person to actively administer carbohydrate, glucagon, or other resuscitative actions); in DUAL I there 
were three severe events with IDegLira, two with IDeg and none with liraglutide, in DUAL I ext, at the 
end of 52 weeks there were three severe events with IDegLira (those reported in the main DUAL I 
trial), two with IDeg (those reported in the main DUAL I trial) and two with liraglutide,
7
 and in DUAL 
V one severe event with IGlar U100 and none with IDegLira.
3
 For nocturnal hypoglycaemia, rates 
were statistically significantly lower in patients treated with IDegLira than with IDeg for both DUAL I 
and DUAL I ext for the definition of nocturnal confirmed hypoglycaemia (unable to self-treat or <3.1 
mmol/L [<56 mg/dL], 00:017:59 h). For the nocturnal ADA-documented symptomatic 
hypoglycaemia definition, the rate was significantly lower with IDegLira in DUAL I ext (Figure 1A). 
Liraglutide treatment, in comparison with IDegLira, resulted in statistically significantly lower rates of 
hypoglycaemia in DUAL I and DUAL I ext for all definitions except nocturnal confirmed symptomatic 
hypoglycaemia, where statistical analyses could not be carried out due to the low number of events 
in the liraglutide arm.  
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The cumulative mean number of ADA-documented symptomatic episodes per patient for IDegLira, 
IDeg and liraglutide from DUAL I and DUAL I ext are shown in Figure 2A, and for IDegLira and IGlar 
U100 from DUAL V, in Figure 2B. The equivalent data for nocturnal ADA-documented symptomatic 
hypoglycaemia are given in Supplementary Figure 2. For comparison, the cumulative mean number 
of overall and nocturnal events per patient, by treatment, using the original confirmed 
hypoglycaemia definition can be seen in Supplementary Figure 3. 
 
Hypoglycaemia rates by dosing time 
Confirmed hypoglycaemia rates for IDegLira, IDeg and liraglutide when all treatments were dosed in 
the AM were 1.68, 2.76 and 0.22 events per patient-year of exposure (PYE), respectively, in DUAL I 
and 1.66, 3.11 and 0.18 events per PYE in DUAL I ext. When all treatments were dosed in the PM, 
confirmed hypoglycaemia rates for IDegLira, IDeg and liraglutide, respectively were 1.94, 2.42 and 
0.22 events per PYE in DUAL I, and 1.89, 2.53 and 0.20 events per PYE in DUAL I ext. Nocturnal 
confirmed hypoglycaemia rates for IDegLira, IDeg and liraglutide, respectively, when all treatments 
were dosed in the AM were 0.22, 0.29 and 0.01 events per PYE in DUAL I, and 0.22, 0.48 and 0.01 
events per PYE in DUAL I ext. When all treatments were dosed in the PM, the respective confirmed 
nocturnal hypoglycaemia rates were 0.23, 0.27 and 0.05 events per PYE in DUAL I, and 0.23, 0.27 and 
0.03 events per PYE in DUAL I ext. The estimated rate ratios for DUAL I and DUAL I ext show that; in 
patients treated with IDegLira, confirmed hypoglycaemia rates were statistically significantly lower 
than with IDeg for AM dosing of both treatments; for PM dosing of both treatments DUAL I ext 
showed a statistically significant difference between IDegLira and IDeg treatment (Figure 3A). 
Nocturnal confirmed hypoglycaemia rates were lower in patients treated with IDegLira than with 
IDeg, but the difference was only statistically significant for AM dosing of both treatments in DUAL I 
ext. For PM dosing, there was no statistically significant difference between treatment with IDegLira 
and IDeg in DUAL I or DUAL I ext for nocturnal hypoglycaemia (Figure 3A). Compared with IDegLira, 
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treatment with liraglutide resulted in statistically significantly lower rates of confirmed and 
nocturnal confirmed hypoglycaemia, whether both treatments were dosed in the AM or PM, for 
both DUAL I and DUAL I ext (Figure 2B). Confirmed hypoglycaemia rates for IDegLira and IGlar U100 
were 2.18 and 6.86 events per PYE, respectively, when dosed in the AM and 2.26 and 4.59 events 
per PYE when dosed in the PM. Nocturnal confirmed hypoglycaemia rates were 0.22 and 1.67 events 
per PYE, for IDegLira and IGlar U100 respectively, when both treatments were dosed in the AM and 
0.23 and 1.12 events per PYE when dosed in the PM. IDegLira treatment resulted in statistically 
significantly lower rates of confirmed and nocturnal confirmed hypoglycaemia than IGlar U100, 
whether both treatments were dosed in the AM or PM (Figure 3C). 
 
Confirmed and ADA-documented symptomatic hypoglycaemia rates by baseline characteristics 
The analyses of confirmed hypoglycaemia and ADA-documented symptomatic hypoglycaemia 
definitions, according to baseline characteristics of age, gender and BMI showed generally consistent 
rates for both hypoglycaemia definitions for DUAL I (Supplementary Table 1A) and DUAL V 
(Supplementary Table 1B) between the treatment groups. Interaction analyses showed there was no 
statistically significant effect of age, gender or BMI on the estimated treatment rate ratio for 
IDegLira versus IDeg for both confirmed and ADA-documented symptomatic hypoglycaemia (all p 
>0.10). Comparing IDegLira with liraglutide, there was no statistically significant effect of age, gender 
or BMI on the estimated treatment rate ratio for confirmed hypoglycaemia (p=0.2565, p=0.2635 and 
p=0.2372, respectively), but while gender and BMI had no significant effect on ADA-documented 
symptomatic hypoglycaemia rate ratio (p=0.2090 and p=0.0659 , respectively), there was a 
significant difference seen between <65 years and >65 years (p=0.025), with the rate ratio (favouring 
liraglutide) being relatively much greater for patients aged >65 years using this definition.  
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Proportion of patients achieving combined end points 
The proportions of patients achieving an HbA1c less than 7%, or of 6.5% or less, those achieving the 
HbA1c targets with no ADA-documented symptomatic hypoglycaemia, and those achieving these 
targets with no ADA-documented symptomatic hypoglycaemia and no weight gain are given in 
Supplementary Table 2. The odds of achieving an HbA1c less than 7% or of 6.5% or less without ADA-
documented symptomatic hypoglycaemia and without ADA-documented symptomatic 
hypoglycaemia and weight gain were statistically significantly greater with IDegLira than with IDeg 
and IGlar U100 (p<0.0001 for all comparisons). A greater proportion of patients reached these 
targets with liraglutide than with IDegLira, and this difference in odds was statistically significant for 
HbA1c less than 7% with no ADA documented symptomatic hypoglycaemia or weight gain 
(p<0.0001), HbA1c of 6.5% or less with no ADA-documented symptomatic hypoglycaemia (p=0.0006) 
and HbA1c of 6.5% or less with no ADA-documented symptomatic hypoglycaemia or weight gain 
(p=0.0061). It was not significantly different for HbA1c less than 7% with no ADA-documented 
symptomatic hypoglycaemia (p=0.9075). 
Discussion 
IDegLira treatment has previously been shown to result in greater improvements in glycaemic 
control than IDeg
2,7
 or IGlar U100
3
 and despite the greater HbA1c reduction, hypoglycaemia rates 
were lower. The present post-hoc analyses extend this finding to show that confirmed 
hypoglycaemia and nocturnal confirmed hypoglycaemia rates were lower for IDegLira in comparison 
with IDeg and IGlar U100 irrespective of dosing time, and regardless of the hypoglycaemia 
definitions used. One explanation for the lower rates of hypoglycaemia is the glucose-dependant 
mode of action of GLP-1 RAs concomitant to the insulin sparing effect when GLP-1RA is used 
together with insulin. One of the findings of our analysis was that the advantage of IDegLira with 
regard to nocturnal hypoglycaemia was unaffected by the definition of the nocturnal period. It is 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
possible that the insulin degludec component of IDegLira becomes a relatively more critical 
determinant of risk in the nocturnal period as IDeg is associated with low variability in the glucose-
lowering effect across 24 hours and from day to day.
10
 Importantly, a similar finding was made in a 
meta-analysis of data from trials comparing IDeg with IGlar U100.
11
 Here, the number of episodes 
per PYE were again similar across different definitions of nocturnal hypoglycaemia, and the 
advantage of IDeg was preserved.
11
  
The definition of ADA-documented symptomatic hypoglycaemia resulted in greater numbers of 
episodes per PYE than the original definition and this is primarily due to the raised glycaemic 
threshold at which hypoglycaemia is recognised in the ADA definition (г3.9 mmol/L [г70 mg/dL] as 
opposed to <3.1 mmol/L [<56 mg/dL]) combined with the low titration target applied in the trials 
(4.05.0 mmol/L). Higher event rates were also produced by changing the definition of the nocturnal 
period to 00:0107:59 h, possibly due to this including the pre-breakfast self-monitored plasma 
glucose (SMPG) measurement and/or the influence of diabetes therapies within this interval when 
taken at an early breakfast. The profiles for IDegLira, IDeg and liraglutide with regard to the overall 
and nocturnal cumulative mean number of episodes per patient for DUAL I and ext using the ADA-
documented symptomatic hypoglycaemia definition were, however, similar to those previously 
published with the original definitions,
7
 albeit that the number of episodes per PYE were higher with 
the ADA definition. A similar pattern was seen for the profiles of cumulative mean number of 
episodes per patient for IDegLira and IGlar U100 for ADA-documented symptomatic episodes in 
comparison to those previously published for confirmed hypoglycaemia and nocturnal confirmed 
hypoglycaemia.
3
 The profiles of the cumulative mean number of episodes continued to diverge 
throughout the trial , indicating that the difference was not just an effect of the titration phase; 
rather, the benefit appeared to be maintained or even increase with time over the course of the 
trial. 
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The comparisons of confirmed hypoglycaemia and ADA-documented symptomatic hypoglycaemia 
according to the baseline characteristics indicated consistency in the treatment difference between 
IDegLira and IDeg, liraglutide or IGlar U100, for either hypoglycaemia definition, across the age, sex 
and BMI categories. Overall, the outcomes according to age, sex and BMI further highlight the 
benefits of treatment with IDegLira across a variety of populations of patients with type 2 
diabetes.
7,12 
A limitation of this study is that patients were not randomised according to dosing time. A further 
consideration is that hypoglycaemia data from randomized controlled trials are not necessarily 
indicative of real-world hypoglycaemia rates, which tend to be higher.
13
 This may mean that the 
benefits of lower hypoglycaemia rates with IDegLira treatment, versus IDeg and IGlar U100, could be 
even greater in a clinical setting.  However, this remains to be demonstrated, since in practice 
patients may not be titrated to such tight targets as in the trial setting. Another limitation of this 
study is that the analyses were not adjusted for multiplicity.  
In conclusion, treatment with IDegLira, in comparison with IDeg and IGlar U100, results in lower 
rates of hypoglycaemia regardless of dosing time and definition of hypoglycaemia used. This effect is 
observed despite lower HbA1c levels being achieved with IDegLira compared with IDeg and IGlar 
U100. Furthermore, the baseline characteristics of sex and BMI did not have a significant effect on 
the rate ratios across different hypoglycaemia definitions. Patients older than 65 years had a greater 
reduction in hypoglycaemia than patients younger than 65 years.  Therefore, a broad variety of 
patients with type 2 diabetes might expect to reach their treatment targets with low hypoglycaemia 
rates during treatment with IDegLira. 
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Legends to figures: 
Figure 1. Estimated rate ratio of hypoglycaemia by hypoglycaemia definition for (A) IDegLira vs. IDeg 
and (B) IDegLira vs. liraglutide for DUAL I ext and (C) IDegLira vs. IGlar U100 for DUAL V.  
Figure 2. Cumulative mean number of ADA-documented symptomatic hypoglycaemic episodes per 
patient for (A) IDegLira, IDeg and liraglutide for DUAL I and DUAL I ext and (B) IDegLira and IGlar 
U100 in DUAL V.  
Figure 3. Estimated rate ratio of hypoglycaemia (based on original definition) by dosing time for (A) 
IDegLira vs. IDeg and (B) IDegLira vs. liraglutide for DUAL I and DUAL I ext and (C) IDegLira vs. IGlar 
U100 for DUAL V.  
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Figures and Tables 
Table 1. Description of different hypoglycaemia definitions used in analyses. 
 Analysis Description 
D
e
fi
n
it
io
n
 o
f 
h
y
p
o
g
ly
ca
e
m
ia
 Confirmed hypoglycaemia (original) Episodes confirmed by a plasma glucose <3.1 
mmol/L (<56 mg/dL) and/or unable to self-treat 
Overall confirmed symptomatic 
hypoglycaemia 
Episodes confirmed by a plasma glucose <3.1 
mmol/L (<56 mg/dL) and/or unable to self-treat, 
accompanied by reported symptoms 
ADA-documented symptomatic 
hypoglycaemia 
Symptomatic episodes confirmed by a plasma 
glucose г3.9 mmol/L (г70 mg/dL) 
T
im
e
sc
a
le
s 
fo
r 
n
o
ct
u
rn
a
l 
p
e
ri
o
d
 
Nocturnal confirmed hypoglycaemia 
(00:0105:59) 
Episodes confirmed by a plasma glucose <3.1 
mmol/L (<56 mg/dL) and/or unable to self-treat 
occurring between 00:01 and 05:59 h [both 
inclusive] 
Nocturnal confirmed symptomatic 
hypoglycaemia  
Symptomatic episodes confirmed by a plasma 
glucose <3.1 mmol/L (<56 mg/dL) and/or unable to 
self-treat, occurring between 00:01 and 05:59 h 
[both inclusive] 
Nocturnal ADA-documented 
symptomatic hypoglycaemia 
Symptomatic episodes confirmed by a plasma 
glucose г3.9 mmol/L (г70 mg/dL) occurring 
between 00:01 and 05:59 h [both inclusive] 
Nocturnal confirmed hypoglycaemia 
(21:5905:59 h) 
Episodes confirmed by a plasma glucose <3.1 
mmol/L (<56 mg/dL) and/or unable to self-treat 
occurring between 21:59 and 05:59 h [both 
inclusive] 
Nocturnal confirmed hypoglycaemia
(00:0107:59 h) 
Episodes confirmed by a plasma glucose <3.1 
mmol/L (<56 mg/dL) and/or unable to self-treat 
occurring between 00:01 and 07:59 h [both 
inclusive] 
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Table 2. Observed rates of hypoglycaemia. 
 Episodes per PYE 
DUAL I:IDegLira (N=825), IDeg (N=412), liraglutide (N=412) IDegLira IDeg Liraglutide
Confirmed hypoglycaemia (original) 
Main trial period
Trial extension period
1.80 
1.77 
2.56 
2.79 
0.22 
0.19 
Overall confirmed symptomatic hypoglycaemia
Main trial period
Trial extension period
0.67 
0.70 
1.08 
1.13 
0.06 
0.07 
ADA-documented symptomatic hypoglycaemia 
Main trial period
Trial extension period
4.12 
4.20 
5.74 
6.40 
0.35 
0.37 
Nocturnal confirmed hypoglycaemia (00:0105:59 h) 
Main trial period
Trial extension period
0.22 
0.22 
0.28 
0.37 
0.03 
0.02 
Nocturnal confirmed symptomatic hypoglycaemia  
Main trial period
Trial extension period
0.08 
0.09 
0.10 
0.14 
NA 
NA 
Nocturnal ADA-documented symptomatic hypoglycaemia 
Main trial period
Trial extension period
0.54 
0.52 
0.66 
0.83 
0.05 
0.03 
Nocturnal confirmed hypoglycaemia (21:5905:59 h)
Main trial period
Trial extension period
0.24 
0.25 
0.26 
0.32 
0.02 
0.03 
Nocturnal confirmed hypoglycaemia (00:0107:59 h) 
Main trial period
Trial extension period
0.76 
0.78 
1.15 
1.31 
0.09 
0.07 
DUAL V: IDegLira (N=278), insulin glargine U100 (N=279) IDegLira IGlar U100 
Confirmed hypoglycaemia (original) 2.23 5.05 
Overall confirmed symptomatic hypoglycaemia 1.56 3.75
ADA documented symptomatic hypoglycaemia 8.03 15.63 
Nocturnal confirmed hypoglycaemia (00:0105:59 h) 0.22 1.23 
Nocturnal confirmed symptomatic hypoglycaemia  0.16 1.02 
Nocturnal ADA documented symptomatic hypoglycaemia 0.72 2.75
Nocturnal confirmed hypoglycaemia (21:5905:59 h) 0.27 1.35 
Nocturnal confirmed hypoglycaemia (00:0107:59) 1.17 2.94 
Data based on the safety analysis set. ADA, American Diabetes Association; IDeg, insulin degludec; IDegLira, insulin degludec/liraglutide 
combination; IGlar U100, insulin glargine 100 units/mL; PYE, patient-year of exposure; NA, not applicable. 
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